Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 43 articles: HTML format

Single Articles

October 2025
1. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
   Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
   Br J Cancer. 2025;133:874-885.
   PubMed     Abstract available
   
   
   September 2025
2. MAY M, Gilfrich C, Enzinger B, Brookman-May S, et al
   Exercise oncology in prostate cancer: from observational insight to prescriptive precision.
   Br J Cancer. 2025 Sep 16. doi: 10.1038/s41416-025-03205.
   PubMed    
   
   
   
3. HUANG H, Benzonana LL, Zhao H, Watts HR, et al
   Correction to: Prostate cancer cell malignancy via modulation of HIF-1alpha pathway with isoflurane and propofol alone and in combination.
   Br J Cancer. 2025 Sep 5. doi: 10.1038/s41416-025-03175.
   PubMed    
   
   
   July 2025
4. AN KY, Jeon JY, Arthuso FZ, Wang Q, et al
   Postdiagnosis physical activity is associated with improved survival in prostate cancer patients treated with surgery but not with radiation therapy.
   Br J Cancer. 2025 Jul 23. doi: 10.1038/s41416-025-03123.
   PubMed     Abstract available
   
   
   
5. FLAHERTY RL, Falcinelli M, Hesketh AR, Patel BA, et al
   Biomarkers of psychological stress are associated with increased susceptibility to the development of breast and prostate cancer in BRCA1/2 mutation carriers.
   Br J Cancer. 2025 Jul 2. doi: 10.1038/s41416-025-03085.
   PubMed     Abstract available
   
   
   April 2025
6. LI X, Mamouni K, Zhao R, Bai L, et al
   Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer.
   Br J Cancer. 2025 Apr 19. doi: 10.1038/s41416-025-02993.
   PubMed     Abstract available
   
   
   
7. HARTLEY A, Galbraith LCA, Shaw R, Tibbo A, et al
   Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos.
   Br J Cancer. 2025;132:502-512.
   PubMed     Abstract available
   
   
   March 2025
8. LI GX, Ma B, Zhang S, Liu R, et al
   EphB4-ephrin-B2 are targets in castration resistant prostate cancer.
   Br J Cancer. 2025 Mar 5. doi: 10.1038/s41416-025-02942.
   PubMed     Abstract available
   
   
   
9. O'SULLIVAN JM, Heinrich D, Castro E, George S, et al
   Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study.
   Br J Cancer. 2025;132:354-360.
   PubMed     Abstract available
   
   
   February 2025
10. LIN SC, Cheng YS, Lin YS, Nguyen TMH, et al
    The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance.
    Br J Cancer. 2025 Feb 16. doi: 10.1038/s41416-025-02938.
    PubMed     Abstract available
    
    
    
11. VAN DER KLEIJ MBA, Meertens M, Groenland SL, Kordes S, et al
    Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.
    Br J Cancer. 2025 Feb 11. doi: 10.1038/s41416-025-02954.
    PubMed     Abstract available
    
    
    
12. WANG R, Wang S, Mi Y, Huang T, et al
    Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study.
    Br J Cancer. 2025 Feb 3. doi: 10.1038/s41416-025-02947.
    PubMed     Abstract available
    
    
    December 2024
13. LUO L, Wang R, Bai L, Shang J, et al
    The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone.
    Br J Cancer. 2024 Dec 19. doi: 10.1038/s41416-024-02934.
    PubMed     Abstract available
    
    
    
14. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    PubMed     Abstract available
    
    
    
15. CHEN M, Zhou S, He X, Wen H, et al
    Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation.
    Br J Cancer. 2024 Dec 15. doi: 10.1038/s41416-024-02922.
    PubMed     Abstract available
    
    
    October 2024
16. RAHMAN R, Rahaman MH, Hanson AR, Choo N, et al
    Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
    Br J Cancer. 2024 Oct 24. doi: 10.1038/s41416-024-02862.
    PubMed    
    
    
    
17. SHEN M, Garcia-Marques F, Muruganantham A, Liu S, et al
    Identification of a 5-gene signature panel for the prediction of prostate cancer progression.
    Br J Cancer. 2024 Oct 14. doi: 10.1038/s41416-024-02854.
    PubMed     Abstract available
    
    
    September 2024
18. CHOW ST, Fan J, Zhang X, Wang Y, et al
    Nuclear receptor TLX functions to promote cancer stemness and EMT in prostate cancer via its direct transactivation of CD44 and stem cell-regulatory transcription factors.
    Br J Cancer. 2024 Sep 26. doi: 10.1038/s41416-024-02843.
    PubMed     Abstract available
    
    
    
19. WANG T, Wang X, Ding G, Liu H, et al
    Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.
    Br J Cancer. 2024 Sep 2. doi: 10.1038/s41416-024-02823.
    PubMed     Abstract available
    
    
    August 2024
20. NTURUBIKA BD, Guardia CM, Gershlick DC, Logan JM, et al
    Altered expression of vesicular trafficking machinery in prostate cancer affects lysosomal dynamics and provides insight into the underlying biology and disease progression.
    Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02829.
    PubMed     Abstract available
    
    
    
21. RAHMAN R, Rahaman MH, Hanson AR, Choo N, et al
    CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
    Br J Cancer. 2024 Aug 8. doi: 10.1038/s41416-024-02810.
    PubMed     Abstract available
    
    
    July 2024
22. LIN BB, Huang Q, Yan B, Liu M, et al
    An 18-gene signature of recurrence-associated endothelial cells predicts tumor progression and castration resistance in prostate cancer.
    Br J Cancer. 2024 Jul 12. doi: 10.1038/s41416-024-02761.
    PubMed     Abstract available
    
    
    
23. PUJANA-VAQUERIZO M, Bozal-Basterra L, Carracedo A
    Metabolic adaptations in prostate cancer.
    Br J Cancer. 2024 Jul 5. doi: 10.1038/s41416-024-02762.
    PubMed     Abstract available
    
    
    
24. CYLL K, Skaaheim Haug E, Pradhan M, Vlatkovic L, et al
    DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.
    Br J Cancer. 2024 Jul 3. doi: 10.1038/s41416-024-02780.
    PubMed     Abstract available
    
    
    June 2024
25. ARMAKOLAS A, Alevizopoulos N, Stathaki M, Petraki C, et al
    Anti-PEc: Development of a novel monoclonal antibody against prostate cancer.
    Br J Cancer. 2024 Jun 20. doi: 10.1038/s41416-024-02713.
    PubMed     Abstract available
    
    
    March 2024
26. ZHANG Y, Stopsack KH, Wu K, Song M, et al
    Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer.
    Br J Cancer. 2024 Mar 15. doi: 10.1038/s41416-024-02651.
    PubMed     Abstract available
    
    
    
27. GNANAPRAGASAM V
    Shifting the paradigm in the management of early prostate cancer.
    Br J Cancer. 2024 Mar 6. doi: 10.1038/s41416-024-02641.
    PubMed     Abstract available
    
    
    February 2024
28. EBERLEIN C, Williamson SC, Hopcroft L, Ros S, et al
    Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
    Br J Cancer. 2024 Feb 23. doi: 10.1038/s41416-024-02614.
    PubMed     Abstract available
    
    
    
29. LIU Q, Zhang Y, Vaselkiv JB, Mucci LA, et al
    A prospective study of birth weight and prostate cancer risk and mortality in the Health Professionals Follow-up Study.
    Br J Cancer. 2024 Feb 22. doi: 10.1038/s41416-024-02593.
    PubMed     Abstract available
    
    
    
30. CONSTANTIN TA, Varela-Carver A, Greenland KK, de Almeida GS, et al
    Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
    Br J Cancer. 2024 Feb 14. doi: 10.1038/s41416-024-02606.
    PubMed    
    
    
    
31. O'MALLEY DE, Raspin K, Melton PE, Burdon KP, et al
    Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.
    Br J Cancer. 2024;130:347-357.
    PubMed     Abstract available
    
    
    January 2024
32. MAH CY, Nguyen ADT, Niijima T, Helm M, et al
    Peroxisomal beta-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer.
    Br J Cancer. 2024 Jan 12. doi: 10.1038/s41416-023-02557.
    PubMed     Abstract available
    
    
    December 2023
33. FRITZ J, Jochems SHJ, Bjorge T, Wood AM, et al
    Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts.
    Br J Cancer. 2023 Dec 12. doi: 10.1038/s41416-023-02526.
    PubMed     Abstract available
    
    
    November 2023
34. ZHAO JL, Antonarakis ES, Cheng HH, George DJ, et al
    Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
    Br J Cancer. 2023 Nov 18. doi: 10.1038/s41416-023-02487.
    PubMed     Abstract available
    
    
    
35. SHEN J, Chowdhury S, Agarwal N, Karsh LI, et al
    Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
    Br J Cancer. 2023 Nov 11. doi: 10.1038/s41416-023-02492.
    PubMed     Abstract available
    
    
    
36. AHMAD AS, Offman J, Delon C, North BV, et al
    Years of life lost due to cancer in the United Kingdom from 1988 to 2017.
    Br J Cancer. 2023;129:1558-1568.
    PubMed     Abstract available
    
    
    
37. CAMERON JM, Sala A, Antoniou G, Brennan PM, et al
    A spectroscopic liquid biopsy for the earlier detection of multiple cancer types.
    Br J Cancer. 2023;129:1658-1666.
    PubMed     Abstract available
    
    
    
38. SHEN M, Liu S, Toland A, Hsu EC, et al
    ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
    Br J Cancer. 2023;129:1818-1828.
    PubMed     Abstract available
    
    
    October 2023
39. FENG X, Zhang Y, Vaselkiv JB, Li R, et al
    Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.
    Br J Cancer. 2023 Oct 28. doi: 10.1038/s41416-023-02472.
    PubMed     Abstract available
    
    
    
40. TURPIN A, Delliaux C, Parent P, Chevalier H, et al
    Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
    Br J Cancer. 2023 Oct 24. doi: 10.1038/s41416-023-02449.
    PubMed     Abstract available
    
    
    
41. GULLIVER C, Huss S, Semjonow A, Baillie GS, et al
    Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies.
    Br J Cancer. 2023;129:1462-1476.
    PubMed     Abstract available
    
    
    September 2023
42. HOU Y, Jiang KW, Wang LL, Zhi R, et al
    Biopsy-free AI-aided precision MRI assessment in prediction of prostate cancer biochemical recurrence.
    Br J Cancer. 2023 Sep 27. doi: 10.1038/s41416-023-02441.
    PubMed     Abstract available
    
    
    
43. HINNEH JA, Gillis JL, Mah CY, Irani S, et al
    Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
    Br J Cancer. 2023 Sep 6. doi: 10.1038/s41416-023-02406.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.